PHARMACO-KINESIS' METRONOMIC BIOFEEDBACK PUMP (MBP) TO BE PRESENTED BY DR. THOMAS CHEN, MD, PH.D. AT INTERNATIONAL SYMPOSIA
Dr. Chen announced as speaker and co-Chair of Symposium 6: Advances in Drug Delivery against Major Cancers at IDDST-2010

INGLEWOOD, CALIFORNIA, August 3, 2010 – Pharmaco-Kinesis Corporation (PKC), an advanced medical device company developing smart local drug delivery systems, today reported Dr. Thomas C. Chen's participation as co-chair of Symposium 6 and speaker at the 2010 International Drug Discovery Science and Technology (IDDST-2010). Dr. Chen will discuss PKC's MBP and the merits of personalized medicine utilizing local, metronomic drug delivery delivered through a fully implantable device.

IDDST-2010, sponsored by BIT Life Sciences, will hold its annual conference between October 23 and 26 at the National Convention Center in Beijing, China. This important international Symposia will focus on Cancer Drug Delivery, and will provide excellent exposure for PKC's MBP device and its supporting technology.

The MBP is an implantable and remotely programmable pump that can deliver multiple medications directly to a tumor site or organ, with real time measurement of bioresponse in the form of VEGF levels, temperature and pressure. PKC has nearly completed its third phase of miniaturization on the MBP device, and will begin animal studies in late August 2010. These trials will test the functionality, reliability and accuracy of the MPB prior to commencing Phase I/II studies in humans, which are expected to commence in 2011.

The first application of the MPB is expected for treatment of Leptomeningeal Carcinomatosis (LC), a devastating complication of cancer that attacks the brain and travels in the spinal fluid. “Despite significant improvements in chemotherapy, radiation therapy and surgery for many types of cancer, the prognosis is dismal for patients with LC. Untreated patients survive for approximately 6-8 weeks, and even with aggressive treatment using current methods, the average survival for LC patients with solid tumors is approximately 4-8 months.” said Thomas C. Chen, M.D., Chief Oncology Officer of PKC. “Multiple studies have shown that continuous flow of medication, administration of alternate drug regimens or drug combinations, and adaptation of dosage to individualized patient needs can improve survival rates, but as yet no device has been developed with these capabilities. The MBP can improve the survival rates and the quality of life of LC patients." 

“We believe the MPB represents an outstanding commercial opportunity for the medical device industry and for pharmaceutical companies,” said Frank Adell, CEO of PKC. “The MBP can serve as a catalyst for pharmaceutical companies to reformulate generic medications and gain new market potential while improving the safety and efficacy of their products. Spreading the word about PKC's working MBP prototype within the scientific community is an important aspect in creating value for our shareholders. This is why we are so pleased that Dr. Chen will lend his experience and reputation to discussing the MBP in this important international forum."

The PKC R&D team is engaged in several product development programs for commercialization of novel smart local drug delivery technologies and advanced devices to measure biological responses.

For additional information, please contact:
Daniel Saks Senior
Vice President, Corporate Affairs
Pharmaco-Kinesis Corporation
(310) 734-4447